{"id":8293,"date":"2023-08-10T12:55:18","date_gmt":"2023-08-10T12:55:18","guid":{"rendered":"https:\/\/www.caltagmedsystems.co.uk\/information\/?p=8293"},"modified":"2023-08-10T12:55:18","modified_gmt":"2023-08-10T12:55:18","slug":"il-18-therapies-targeting-inflammatory-disease","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/il-18-therapies-targeting-inflammatory-disease\/","title":{"rendered":"IL-18 Therapies Targeting Inflammatory Disease"},"content":{"rendered":"\n
\"\"<\/a><\/figure>\n\n\n\n

Due to the biological properties of IL-18 and its pathological role in different diseases, it is not surprising that drug discovery and therapies are focused on IL-18 and the control of its more pathological outcomes. Using monoclonal antibodies, IL-18 is prevented by inhibiting its production in cells and its secretion from cells. However, most monoclonal antibody therapies that target IL-18 alone had only partial effectiveness or complete ineffectiveness in vitro, in vivo, and human studies (2). The unsuccessfulness of these monoclonal antibodies targeting IL-18 alone may be more due to the contribution of the intrinsic involvement of other cytokines and proteins in the signalling pathway of many inflammatory diseases. Currently, drug therapy is becoming more focused on IL-18 inhibitors or agonists in addition to other cytokines.<\/p>\n\n\n\n

The table summarises some of the IL-18 inhibitors and IL-18BP drugs in clinical trials and preclinical studies for the treatment of inflammatory diseases.<\/p>\n\n\n\n

Drug Category<\/strong><\/td>Application<\/strong><\/td>Mechanism<\/strong><\/td>Clinical Phase Status<\/strong><\/td><\/tr>
Recombinant human IL-18 binding protein<\/td>Macrophage Activation Syndrome\/Immune System Diseases\/Adult-Onset Still\u2019s Disease<\/td>IL-18 inhibitor<\/td>Phase III<\/td><\/tr>
Biological products<\/td>Atopic Dermatitis\/Pulmonary Sarcoidosis<\/td>IL-18 inhibitor<\/td>Phase II<\/td><\/tr>
Monoclonal antibody<\/td>Adult-Onset Still\u2019s Disease\/Autoimmune Diseases<\/td>IL-18 inhibitor<\/td>Phase I<\/td><\/tr>
Biological products<\/td>Melanoma\/Carcinoma\/Non-Small Cell Lung Cancer<\/td>IL-18 agonist<\/td>Phase II<\/td><\/tr>
Fusion protein<\/td>Adult-Onset Still\u2019s Disease\/Rheumatoid Arthritis\/Inflammatory Bowel Diseases<\/td>IL-18 inhibitor<\/td>Drug discovery<\/td><\/tr>
Recombinant human IL-18 binding protein<\/td>Psoriasis\/Rheumatoid Arthritis\/Crohn Disease\/Autoimmune Diseases<\/td>IL-18 inhibitor<\/td>Phase II (Terminated)<\/td><\/tr>
Fusion protein<\/td>Psoriasis\/Myocardial Ischemia\/Neoplasm Metastasis<\/td>IL-18 Inhibitor, IL-1R1 antagonist<\/td>Psoriasis\/Rheumatoid Arthritis\/Crohn’s Disease\/Autoimmune Diseases<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

L-18 performs a critical role in the pathogenesis of some inflammatory diseases. IL-18 inhibitors and IL-18BP agonists are promising candidates for the therapy of diverse medical conditions, including acute and chronic inflammation. Clinical studies are indicating the prominent role of IL-18 in Psoriasis, MG, and other diseases. Nonetheless, additional research and clinical trials of IL-18 BP and other antibodies are necessary to properly ascertain the role of IL-18 in treating inflammatory diseases. Hence, research will continue into IL-BP and other drugs affecting IL-18 for the treatment and control of pathogenic inflammatory conditions.

MBL International offers a wide variety of products to help in the research of IL-18.<\/p>\n\n\n\n

Product Code<\/strong><\/td>Product Name<\/strong> <\/td><\/tr>
7620\u00a0<\/a><\/strong><\/td>Human IL-18 ELISA Kit<\/td><\/tr>
D044-3M2<\/a><\/strong><\/td>Anti-IL-18 (Clone 125-2H) (Human) mAb (Functional Grade) (Monoclonal Antibody)<\/td><\/tr>
B001-5<\/a><\/strong><\/td>Recombinant Human IL-18<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

REFERENCES:<\/p>\n\n\n\n

    \n
  1. Harel, Mathilde, et al. “Balance between interleukin-18 and interleukin-18 binding protein in auto-inflammatory diseases.” Cytokine 150 (2022): 155781.<\/li>\n\n\n\n
  2. Ihim, Stella Amarachi, et al. “Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment.” Frontiers in Immunology (2022): 4470.<\/li>\n<\/ol>\n\n\n\n

    Originally posted on blog.mblintl.com\/il-18-therapies-targeting-inflammatory-disease<\/a><\/p>\n\n\n\n

    Caltag Medsystems\u00a0<\/a>is the distributor of\u00a0MBL International<\/a>\u00a0products in the UK and Ireland. If you have any questions about these products, please\u00a0contact us<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

    MBL International offers a wide variety of products to help in the research of IL-18.<\/p>\n","protected":false},"author":13,"featured_media":8297,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[73,1,622],"tags":[693,265,67],"class_list":["post-8293","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-discovery","category-general-information","category-inflammation","tag-il-18","tag-inflammation","tag-mbl-international"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=8293"}],"version-history":[{"count":3,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8293\/revisions"}],"predecessor-version":[{"id":8298,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8293\/revisions\/8298"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/8297"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=8293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=8293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=8293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}